Polymeric nanotheranostics for real-time non-invasive optical imaging of breast cancer progression and drug release

Cancer Letters

Volumn 352, Issue 1, 2014, Pages 81-89

  Ferber, Shiran ^a   Baabur Cohen, Hemda ^a   Blau, Rachel ^a   Epshtein, Yana ^a   Kisin Finfer, Einat ^a   Redy, Orit ^a   Shabat, Doron ^a   Satchi Fainaro, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Breast cancer; NIR fluorophore; Paclitaxel; Polymeric nanomedicines; Theranostics; Tumor targeting

Indexed keywords

ANTINEOPLASTIC AGENT; CATHEPSIN B; COPOLYMER; DIAGNOSTIC AGENT; FLUORESCENT DYE; N (2 HYDROXYPROPYL)METHACRYLAMIDE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER PACLITAXEL CONJUGATE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER SQ CY5 CONJUGATE; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; BIOLOGICAL MONITORING; BREAST ADENOCARCINOMA; BREAST CANCER CELL LINE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER GROWTH; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG HALF LIFE; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; ENZYMATIC DEGRADATION; FEMALE; FLUORESCENCE IMAGING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOMEDICINE; NANOPHARMACEUTICS; NEAR INFRARED SPECTROSCOPY; NON INVASIVE MEASUREMENT; NONHUMAN; POLYMERIC NANOTHERANOSTICS; PRIORITY JOURNAL;

MURINAE; MUS;

BREAST CANCER; NIR FLUOROPHORE; PACLITAXEL; POLYMERIC NANOMEDICINES; THERANOSTICS; TUMOR TARGETING;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DIAGNOSTIC IMAGING; DRUG CARRIERS; FEMALE; FLUORESCENT DYES; METHACRYLATES; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; NANOSTRUCTURES; PACLITAXEL;

EID: 84906056644     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.02.022     Document Type: Article

References (41)

1. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug. Discov. 2008, 7:771-782.
2. Joshi B.P., Wang T.D. Exogenous molecular probes for targeted imaging in cancer: focus on multi-modal imaging. Cancers 2010, 2:1251-1287.
3. Mothes H., Dinkelaker T., Donicke T., Friedel R., Hofmann G., Bach O. Outcome prediction in microsurgery by quantitative evaluation of perfusion using ICG fluorescence angiography. J. Hand Surg.-Eur. 2009, 34E:238-246.
4. Kelkar S.S., Reineke T.M. Theranostics: combining imaging and therapy. Bioconjugate Chem. 2011, 22:1879-1903.
5. Janib S.M., Moses A.S., MacKay J.A. Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliver Rev. 2010, 62:1052-1063.
6. McCarthy J.R. The future of theranostic nanoagents. Nanomedicine 2009, 4:693-695.
7. Longmire M., Kosaka N., Ogawa M., Choyke P.L., Kobayashi H. Multicolor in vivo targeted imaging to guide real-time surgery of HER2-positive micrometastases in a two-tumor coincident model of ovarian cancer. Cancer Sci. 2009, 100:1099-1104.
8. Ogawa M., Regino C.A.S., Choyke P.L., Kobayashi H. In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies. Mol. Cancer Ther. 2009, 8:232-239.
9. Iyer A.K., Khaled G., Fang J., Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 2006, 11:812-818.
10. Eldar-Boock A., Polyak D., Scomparin A., Satchi-Fainaro R. Nano-sized polymers and liposomes designed to deliver combination therapy for cancer. Curr. Opin. Biotechnol. 2013, 24:682-689.
11. Billinton N., Knight A.W. Seeing the wood through the trees: a review of techniques for distinguishing green fluorescent protein from endogenous autofluorescence. Anal. Biochem. 2001, 291:175-197.
12. Monici M. Cell and tissue autofluorescence research and diagnostic applications. Biotechnol. Ann. Rev. 2005, 11:227-256.
13. Feng L., Yoo K.M., Alfano R.R. Ultrafast laser-pulse transmission and imaging through biological tissues. Appl. Opt. 1993, 32:554-558.
14. Boppart S.A., Oldenburg A.L., Xu C., Marks D.L. Optical probes and techniques for molecular contrast enhancement in coherence imaging. J. Biomed. Opt. 2005, 10:41208.
15. Demos S.G., Radousky H.B., Alfano R.R. Deep subsurface imaging in tissues using spectral and polarization filtering. Opt. Express 2000, 7:23-28.
16. Pansare V., Hejazi S., Faenza W., Prud'homme R.K. Review of long-wavelength optical and NIR imaging materials: contrast agents, fluorophores and multifunctional nano carriers. Chem. Mater. Publ. Am. Chem. Soc. 2012, 24:812-827.
17. S. Lee, J. Xie, X. Chen, Activatable molecular probes for cancer imaging, 2010.
18. Karton-Lifshin N., Segal E., Omer L., Portnoy M., Satchi-Fainaro R., Shabat D. A unique paradigm for a Turn-ON near-infrared cyanine-based probe: noninvasive intravital optical imaging of hydrogen peroxide. J. Am. Chem. Soc. 2011, 133:10960-10965.
19. Kobayashi H., Ogawa M., Alford R., Choyke P.L., Urano Y. New strategies for fluorescent probe design in medical diagnostic imaging. Chem. Rev. 2010, 110:2620-2640.
20. Lee S., Park K., Kim K., Choi K., Kwon I.C. Activatable imaging probes with amplified fluorescent signals. Chem. Commun. (Camb.) 2008, 4250-4260.
21. Johansson M.K., Fidder H., Dick D., Cook R.M. Intramolecular dimers: a new strategy to fluorescence quenching in dual-labeled oligonucleotide probes. J. Am. Chem. Soc. 2002, 124:6950-6956.
22. Redy O., Kisin-Finfer E., Sella E., Shabat D. A simple FRET-based modular design for diagnostic probes. Org. Biomol. Chem. 2012, 10:710-715.
23. Melancon M.P., Wang W., Wang Y., Shao R., Ji X., Gelovani J.G., Li C. A novel method for imaging in vivo degradation of poly(L-glutamic acid), a biodegradable drug carrier. Pharm. Res. 2007, 24:1217-1224.
24. Weinstain R., Segal E., Satchi-Fainaro R., Shabat D. Real-time monitoring of drug release. Chem. Commun. (Camb.) 2010, 46:553-555.
25. Kopecek J., Kopeckova P. HPMA copolymers: origins, early developments, present, and future. Adv. Drug Deliv. Rev. 2010, 62:122-149.
26. Lammers T., Ulbrich K. HPMA copolymers: 30 years of advances. Adv. Drug Deliv. Rev. 2010, 62:119-121.
27. Iacobuzio-Donahue C.A., Shuja S., Cai J., Peng P., Murnane M.J. Elevations in cathepsin B protein content and enzyme activity occur independently of glycosylation during colorectal tumor progression. J. Biol. Chem. 1997, 272:29190-29199.
28. Sinha A.A., Quast B.J., Wilson M.J., Reddy P.K., Gleason D.F., Sloane B.F. Codistribution of procathepsin B and mature cathepsin B forms in human prostate tumors detected by confocal and immunofluorescence microscopy. Anat. Rec. 1998, 252:281-289.
29. Premzl A., Turk V., Kos J. Intracellular proteolytic activity of cathepsin B is associated with capillary-like tube formation by endothelial cells in vitro. J. Cell. Biochem. 2006, 97:1230-1240.
30. Malla R.R., Gopinath S., Gondi C.S., Alapati K., Dinh D.H., Gujrati M., Rao J.S. Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma. Cancer Gene Ther. 2011, 18:419-434.
31. Koblinski J.E., Ahram M., Sloane B.F. Unraveling the role of proteases in cancer. Clin. Chim. Acta 2000, 291:113-135.
32. Duncan R., Gac-Breton S., Keane R., Musila R., Sat Y.N., Satchi R., Searle F. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J. Control Release 2001, 74:135-146.
33. Miller K., Erez R., Segal E., Shabat D., Satchi-Fainaro R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew. Chem. Int. Ed. Engl. 2009, 48:2949-2954.
34. Miller K., Eldar-Boock A., Polyak D., Segal E., Benayoun L., Shaked Y., Satchi-Fainaro R. Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model. Mol. Pharm. 2011, 8:1052-1062.
35. Clementi C., Miller K., Mero A., Satchi-Fainaro R., Pasut G. Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms. Mol. Pharm. 2011, 8:1063-1072.
36. Weissleder R., Tung C.H., Mahmood U., Bogdanov A. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat. Biotechnol. 1999, 17:375-378.
37. Yang Z., Lee J.H., Jeon H.M., Han J.H., Park N., He Y., Lee H., Hong K.S., Kang C., Kim J.S. Folate-based near-infrared fluorescent theranostic gemcitabine delivery. J. Am. Chem. Soc. 2013, 135:11657-11662.
38. Lee M.H., Kim J.Y., Han J.H., Bhuniya S., Sessler J.L., Kang C., Kim J.S. Direct fluorescence monitoring of the delivery and cellular uptake of a cancer-targeted RGD peptide-appended naphthalimide theragnostic prodrug. J. Am. Chem. Soc. 2012, 134:12668-12674.
39. Lee J.S., Groothuis T., Cusan C., Mink D., Feijen J. Lysosomally cleavable peptide-containing polymersomes modified with anti-EGFR antibody for systemic cancer chemotherapy. Biomaterials 2011, 32:9144-9153.
40. Splith K., Hu W., Schatzschneider U., Gust R., Ott I., Onambele L.A., Prokop A., Neundorf I. Protease-activatable organometal-Peptide bioconjugates with enhanced cytotoxicity on cancer cells. Bioconjugate Chem. 2010, 21:1288-1296.
41. Eldar-Boock A., Miller K., Sanchis J., Lupu R., Vicent M.J., Satchi-Fainaro R. Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel. Biomaterials 2011, 32:3862-3874.